Selecta Biosciences and AskBio Announce Strategic Partnership

12:16 EDT 7 Aug 2019 | Investing News Network

Selecta Biosciences (NASDAQ:SELB) and Asklepios BioPharmaceutical have announced a strategic partnership to develop targeted therapeutics for adeno-associated virus (AAV) gene therapies. As quoted in the press release: This partnership will leverage the unique proprietary technology platforms of both companies with a human proof of concept trial to validate the potential for re-dosing in patients with … Continued

The post Selecta Biosciences and AskBio Announce Strategic Partnership appeared first on Investing News Network.

Original Article: Selecta Biosciences and AskBio Announce Strategic Partnership


More From BioPortfolio on "Selecta Biosciences and AskBio Announce Strategic Partnership"

Quick Search

Relevant Topics

Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...